Dosing Guidance Lacking For Leading COVID-19 Antiviral Therapies, ASHP Analysis Shows

Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir. 

Coronavirus

The limited amount of data to guide dosing of antiviral therapies for the novel coronavirus stands out in the American Society of Health-System Pharmacists’ assessment of the evidence available for potential COVID-19 treatments.

ASHP created the evidence table to “help practitioners better understand current approaches related to treatment and care,” and noted “the uniqueness of each medical

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D